Abstract #3194

Glutamate imaging in schizophrenia prodrome

Zhuozhi Dai^1,2, Handi Zhang³, Alan H. Wilman¹, Haiyun Xu³, Gang Xiao⁴, Hongfu Sun⁵, Zerui Zhuang⁶, Yanlong Jia⁶, Zhiwei Shen⁶, Gen Yan⁷, and Renhua Wu⁶

¹University of Alberta, Edmonton, AB, Canada, ²Radiology, 2nd Affiliated Hospital of Shantou University Medical College, Shantou, China, ³Mental Health Center of Shantou University, Shantou, China, ⁴Mathematics and Information Technology, Hanshan Normal University, Chaozhou, China, ⁵Hotchkiss Brain Institute, Calgary, AB, Canada, ⁶2nd Affiliated Hospital of Shantou University Medical College, Shantou, China, ⁷Affiliated Hospital of Jiangnan University, Wuxi, China

The diagnosis of schizophrenia prodrome is significant since early intervention may prevent the development of full-blown schizophrenia. With increasing evidence indicating that glutamate is involved in the incidence of schizophrenia, we hypothesize that glutamate could be an imaging biomarker in the diagnosis of prodromal schizophrenia. We applied the glutamate CEST imaging technique in schizophrenic models and demonstrates that glutamate changes in different regions of the brain at an early stage, which may provide a powerful indicator of the diagnosis of schizophrenia prodrome. In addition, the glutamate CEST image had excellent correlation with standard MR spectroscopy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here